Overview

Comparison of Keppra and Clonidine in the Treatment of Tics

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this study is to confirm that levetiracetam has a better tic-suppressing profile than that of the widely used tic-suppressing medication, clonidine. More specifically, the investigators hypothesize that in a 15 week placebo run-in, double-blind, medication cross-over trial; levetiracetam will be more effective and have fewer side-effects than clonidine.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Harvey S. Singer
Collaborator:
UCB Pharma
Treatments:
Clonidine
Etiracetam
Levetiracetam
Piracetam
Criteria
Inclusion Criteria:

Patients will be included in this study if they meet the following criteria:

- Tourette syndrome criteria based on the TS Classification Study Group [1993], which
includes onset before 18 years, multiple involuntary motor tics, one or more vocal
tics, a waxing and waning course, the gradual replacement of old symptoms with new
ones, the presence of tics for more than one year, the absence of other medical
explanations for tics, and observation of tics by a reliable examiner;

- Age 7 to 19 years, either gender;

- Observable tics, achieving a minimum score of > 22 on the Total Tic score of Yale
Global Tic Severity Scale (YGTSS);

- Tic symptoms severe enough to warrant therapy;

- The concurrent use of other tic-suppressing medications will be permitted, if the
subject has been on a stable dose for more than three weeks and agrees to maintain a
constant dosage throughout the study;

- Tics are not controlled with current medication or individuals are tic suppressing
drug naive.

Exclusion Criteria:

Exclusion criteria include the following:

- Secondary tics;

- Significant medical illness

- Current major depression, generalized anxiety disorder, separation anxiety disorder,
psychotic symptoms (based on clinical evaluation), pervasive developmental disorder,
autism, mental retardation (I.Q. less than 70), anorexia/bulimia, or substance abuse.
Subjects with co-morbid ADHD, obsessive compulsive disorder (OCD), and conduct
disorder will not be excluded;

- pregnancy;

- Hypersensitivity to levetiracetam or clonidine;

- baseline weight of less than 25 kilograms.